Michelson Diagnostics strengthens Board with top MedTech Industry Executive, Brian Howlett
(Orpington, UK) May 19, 2010 – Michelson Diagnostics Ltd is pleased to announce that Brian Howlett has joined as non-executive Director. Brian retired from his position as CEO of AIM-listed Lombard Medical in 2009, and brings to Michelson more than 20 years of leadership experience in the medical device industry.
While at Lombard (2005-9), Brian led the company from 2005 through 2009 during turbulent times in capital markets, raising £49 million to fund the development of operations to commercialize the Aorfix AAA stent graft in key world markets, primarily the USA. This product now has internationally derived revenues that have grown from £100k in 2005 to £2.1 million, and currently growing 49% year on year. Strategically the Aorfix product is now positioned with a unique label claim in the EU that clearly differentiates it from the competition and a similar regulatory approval is in sight in the US. Prior to this Brian was General Manager at Boston Scientific Ltd (1999-2005), the UK subsidiary of the giant US medical device company Boston Scientific Inc. During this period, he created a strategic vision for the business which resulted in sales growing from £50M to more than £200M, and it became the most successful European subsidiary of BS Inc. Brian was also Managing Director of COBE Laboratories (now Caridian BCT) for 12 years and held senior positions at FISONS Plc.
Jon Holmes, CEO of Michelson Diagnostics, said “I am delighted that Brian has agreed to join our Board. He has already contributed valuable insights from his experience of bringing new med-tech products to market to our strategy for rapid clinical adoption of our VivoSight scanners.”
Brian Howlett added “I am very pleased that I can help Michelson: the VivoSight product is very exciting with huge global potential, and I look forward to working with Jon and the rest of the management team in forming strategic and operational plans to achieve MDL's corporate objectives.”
About Michelson Diagnostics
Michelson Diagnostics was founded in 2006; it is privately owned and based in Kent, U.K. The company develops imaging products using a technology called Multi-Beam Optical Coherence Tomography. The company’s products include the EX1301 OCT Microscope which is used by researchers in a variety of fields including genetics research, tissue engineering and industrial metrology; and the VivoSight OCT scanner which has CE and 510(k) clearance for use to aid clinical judgments in the field of dermatology. Applications of VivoSight include non-melanoma skin cancer screening and guiding skin cancer surgery.
Further information about Michelson Diagnostics is available on the Internet at http://www.md-ltd.co.uk/ or by email to email@example.com.
For clinical use in the US FDA 510(k) K093520 applies:
The VivoSight Topical OCT system is indicated for use in the two-dimensional, cross-sectional, real-time imaging of external tissues of the human body. This indicated use allows imaging of tissue microstructure, including skin, to aid trained and competent clinicians in their assessment of a patient's clinical conditions. US Federal law restricts this device to sale by or on the order of a physician.
The Michelson Diagnostics logo and the VivoSight name are the trademarks of Michelson Diagnostics Ltd and are registered in the UK, the US & throughout the European Union.